1
Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet
Condition(s):Tuberculosis; Human Immunodeficiency Virus; CoinfectionLast Updated:March 29, 2022Recruiting
Isoniazid, INH Or H, AREA[OverallStatus], Open or Pending: 26 Clinical Trials, Page 1 of 3
Include Studies Not Open or Pending
2
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
Condition(s):Latent Tuberculosis InfectionLast Updated:October 20, 2021Recruiting
3
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
Condition(s):Tuberculosis, PulmonaryLast Updated:April 23, 2021Not yet recruiting
4
Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
Condition(s):Latent Tuberculosis; Kidney FailureLast Updated:August 25, 2021Not yet recruiting
5
Tuberculosis Clinical Trials Consortium Study 35
Condition(s):Latent TuberculosisLast Updated:October 6, 2021Recruiting
6
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Condition(s):HIV Seropositivity; Tuberculosis; Household ContactLast Updated:November 12, 2021Not yet recruiting
7
Novel Triple-dose Tuberculosis Retreatment Regimen
Condition(s):Multidrug-resistant Tuberculosis; Pulmonary Tuberculosis; Tuberculosis; Resistance to Tuberculostatic DrugsLast Updated:November 1, 2021Recruiting
8
Pharmacogenetics-guided Isoniazid Dosing in TB-HIV
Condition(s):TuberculosisLast Updated:January 25, 2022Recruiting
9
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
Condition(s):Tuberculosis; HIV-1-infection; Immuno-DeficiencyLast Updated:May 6, 2022Recruiting
10
Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
Condition(s):Tuberculosis; HIVLast Updated:November 17, 2021Not yet recruiting